08.10.2025
The Eurasian Pharmaceutical Summit 2025, organized by the Global Pharmaceutical Leaders’ Club, took place in Tashkent, Uzbekistan, from October 7 to 9, 2025. The event brought together over 200 pharmaceutical industry leaders from Central Asia, the Caucasus, and Eastern Europe to discuss key strategies, regulatory changes, and industry development prospects.
Last year, Proxima Research participated as an analytical partner. This year, Vitaliy Kim, Director of Proxima Research Uzbekistan, attended the summit as a delegate to listen to expert presentations, meet colleagues, and discuss current trends in the region’s pharmaceutical markets. We had the opportunity to attend key discussions and panel sessions, familiarize ourselves with industry analytics, and review the latest initiatives from both governmental and commercial entities.
Topics such as the digitalization of the pharmaceutical business, emerging opportunities in the industry, regulatory changes, and the growth of local production sparked particular interest among participants. Proxima Research carefully examined the presented cases and initiatives to apply the insights gained further to enhance our analytical and technological solutions for clients.
The summit provided unique opportunities for knowledge exchange and networking with key market players, which is especially valuable for understanding regional trends and prospects for the pharmaceutical sector’s development.
We thank the summit organizers for organizing the event professionally and all participants for engaging in discussions. Proxima Research continues to monitor the development of Eurasian pharmaceutical markets and applies the insights gained to support our clients’ business growth.
By clicking the “Subscribe” button, you consent to the processing of personal data and the receipt of electronic messages about Proxima Research products and services, and you agree to our Terms of Use. Your data will be processed in accordance with our Privacy Policy. You can unsubscribe at any time.
or